semaglutide 75 FDA approves obesity drug that helped people cut weight 15% and increasing feelings of fullness Weight-loss drugs to be offered

The evolving framework under ICH S1B(R1) further emphasizes a modern, evidence-integrated approach to long-term safety evaluation

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of injectable medications used primarily for the management of type 2 diabetes mellitus and, in some formulations, for weight management in adults with obesity or overweight with comorbidities

This was due to the fact that they ushered in a new era in obesity, helping to reshape attitudes to the condition and how it is treated

3234G Q

J Clin Investig 131(12):114

The message of the article is to assess responsibly, know regulations, and provide factual information through available evidence